Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1.
McCormick AL, Parry CM, Crombe A, Goodall RL, Gupta RK, Kaleebu P, Kityo C, Chirara M, Towers GJ, Pillay D. McCormick AL, et al. Among authors: chirara m. Antimicrob Agents Chemother. 2011 Apr;55(4):1806-9. doi: 10.1128/AAC.01197-10. Epub 2011 Jan 31. Antimicrob Agents Chemother. 2011. PMID: 21282419 Free PMC article.
The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data.
Dolling DI, Goodall RL, Chirara M, Hakim J, Nkurunziza P, Munderi P, Eram D, Tumukunde D, Spyer MJ, Gilks CF, Kaleebu P, Dunn DT, Pillay D; DART Virology Group. Dolling DI, et al. Among authors: chirara m. BMC Infect Dis. 2017 Feb 21;17(1):160. doi: 10.1186/s12879-017-2266-3. BMC Infect Dis. 2017. PMID: 28222702 Free PMC article.
Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring.
Lyagoba F, Dunn DT, Pillay D, Kityo C, Robertson V, Tugume S, Hakim J, Munderi P, Chirara M, Ndembi N, Goodall RL, Yirrell DL, Burke A, Gilks CF, Kaleebu P; DART Virology and Trial Team. Lyagoba F, et al. Among authors: chirara m. J Acquir Immune Defic Syndr. 2010 Oct;55(2):277-83. doi: 10.1097/QAI.0b013e3181ea0df8. J Acquir Immune Defic Syndr. 2010. PMID: 20686411
Lack of minority K65R-resistant viral populations detected after repeated treatment interruptions of tenofovir/zidovudine and lamivudine in a resource-limited setting.
McCormick AL, Goodall RL, Joyce A, Ndembi N, Chirara M, Katundu P, Walker S, Yirrell D, Gilks CF, Pillay D; DART Virology Group and Trial Team. McCormick AL, et al. Among authors: chirara m. J Acquir Immune Defic Syndr. 2010 Jun;54(2):215-6. doi: 10.1097/QAI.0b013e3181cc1058. J Acquir Immune Defic Syndr. 2010. PMID: 20505473 Clinical Trial. No abstract available.
Hepatitis B serological markers and plasma DNA concentrations.
Price H, Dunn D, Zachary T, Vudriko T, Chirara M, Kityo C, Munderi P, Spyer M, Hakim J, Gilks C, Kaleebu P, Pillay D, Gilson R; DART Virology Group. Price H, et al. Among authors: chirara m. AIDS. 2017 May 15;31(8):1109-1117. doi: 10.1097/QAD.0000000000001454. AIDS. 2017. PMID: 28328795 Free PMC article. Clinical Trial.
The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models.
Ford D, Robins JM, Petersen ML, Gibb DM, Gilks CF, Mugyenyi P, Grosskurth H, Hakim J, Katabira E, Babiker AG, Walker AS; DART Trial Team. Ford D, et al. Am J Epidemiol. 2015 Oct 1;182(7):633-43. doi: 10.1093/aje/kwv083. Epub 2015 Aug 26. Am J Epidemiol. 2015. PMID: 26316598 Free PMC article. Clinical Trial.
Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda.
Goodall RL, Dunn DT, Pattery T, van Cauwenberge A, Nkurunziza P, Awio P, Ndembi N, Munderi P, Kityo C, Gilks CF, Kaleebu P, Pillay D; DART Virology Group and Trial Teams. Goodall RL, et al. J Antimicrob Chemother. 2014 Jul;69(7):1938-44. doi: 10.1093/jac/dku052. Epub 2014 Mar 14. J Antimicrob Chemother. 2014. PMID: 24633208 Free PMC article. Clinical Trial.
High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.
Kityo C, Gibb DM, Gilks CF, Goodall RL, Mambule I, Kaleebu P, Pillay D, Kasirye R, Mugyenyi P, Walker AS, Dunn DT; DART Trial Team. Kityo C, et al. PLoS One. 2014 Mar 13;9(3):e90772. doi: 10.1371/journal.pone.0090772. eCollection 2014. PLoS One. 2014. PMID: 24625508 Free PMC article. Clinical Trial.
Clinical differences between younger and older adults with HIV/AIDS starting antiretroviral therapy in Uganda and Zimbabwe: a secondary analysis of the DART trial.
Parikh SM, Obuku EA, Walker SA, Semeere AS, Auerbach BJ, Hakim JG, Mayanja-Kizza H, Mugyenyi PN, Salata RA, Kityo CM; DART Trial Team. Parikh SM, et al. PLoS One. 2013 Oct 2;8(10):e76158. doi: 10.1371/journal.pone.0076158. eCollection 2013. PLoS One. 2013. PMID: 24098434 Free PMC article. Clinical Trial.
30 results